These tools support sharing the optimal high-level steps to simplify a process and invite people into the discussion using a common language. The optimal process outlines the essential process steps and for each one lists the ‘who’ (i.e., which role) and the ‘how’ (i.e., what medium). The RACI supports people to understand where accountabilities and responsibilities lie.
Workstreams
Viewing related articles
Accelerating multi-product biopharmaceutical manufacturing facility project lifecycle through modular design
Jun 2022 | Deliverable, Deliverables Report, Publication, Standard Facility Design, Technology Roadmapping
This paper uses a standardized, modular design and construction approach the benefits of a modular design approach to a multi-product viral vector (VV) facility at late-clinical/early-commercial scale, showing how significant speed benefits can be gained at each stage of facility design, procurement, construction, qualification and operation.
BPI Europe May 2022 BSB presentation
May 2022 | Buffer Preparation, Deliverable, Technology Roadmapping, Webinars and podcasts
Forecast and demand planning optimal process tools
May 2022 | Deliverable, Deliverables Report, Forecast and Demand Planning, Forecast and Demand Planning, Publication, Supply Partner
Suite of deliverables to support the forecast and demand planning process and complement the FDP Toolkit. They include an optimal process, RACI and template. These areas are where there is potential for the greatest benefit and will create value for industry when used correctly.
Media and hydrolysates
May 2022 | Cell & Gene Therapy, Deliverable, Drug Substance, Publication, Raw materials, Raw Materials Program, Raw Materials Sourcing
This paper discusses the issues around trace elements and gives a suggested approach for developing a method for analyzing trace elements in cell culture media and hydrolysates. The approach is based on a ground breaking BioPhorum collaboration that shared blinded data and compared analytical methods between biopharmaceutical and media manufacturers.
Member experiences of campaign manufacture with lyophilization processes
May 2022 | Deliverable, Deliverables Report, Fill Finish, Lypholization, Publication
The topic of campaign manufacture for lyophilization processes was discussed by the BioPhorum Lyophilization group. This member only publication is a summary of the approach taken by the major biopharmaceutical companies with experience of campaign manufacture who are members of the group.
Implementation of ready to use cells survey
May 2022 | Benchmarking, Bioassay, Deliverable, Deliverables Report, Development Group
The purpose of this BioPhorum member only survey is to assess the use and control strategy for ready to use (RtU) cells used in bioassays.
Use of forced degradation for formal comparability assessments survey
May 2022 | Benchmarking, Deliverable, Deliverables Report, Development Group, Forced Degradation Studies
This benchmarking survey from the BioPhorum Forced Degradation team has conduced a benchmarking survey for formal comparability assessments.
Ultra high concentration formulation
May 2022 | Benchmarking, Deliverable, Deliverables Report, Development Group, Formulation and Drug Product Development
This member only survey covers the challenges of working with ultra-high concentration formulations, including; low dose volume products, viscosity aspects related to manufacturing and delivery, manufacturing and filling, automated screening, analytical challenges, osmolality considerations (hyper and hypo), syringeability, acceptable injection forces.
Data integrity challenges in the quality control (QC) labs
May 2022 | Deliverable, Deliverables Report, Information Technology, Lab of the Future, Publication
Data integrity is fundamental to comply with current good manufacturing practices (CGMP) and ensure patient safety. Unsurprisingly, quality control (QC) lab data are heavily scrutinized during audits as they directly support the quality, safety and efficacy of the product, and indicate the state of control of a facility. Most QC labs have worked hard to establish the fundamentals of data integrity. Many have digitized to eliminate paper, some systems have compliance features built in, and a series of mitigations and workarounds cover the rest, albeit with some inefficiencies and limitations. There have also been significant evolution of systems and business practices, rising expectations for efficient and thorough investigation capability, and the desire to go beyond compliance and get knowledge and insights through better access to data. Next steps in data integrity are key to the QC lab of the future and the digital maturity of the manufacturing capability as a whole.